News
Cisco today announced it will host Splunk's annual .conf25 user conference from September 8–11, 2025, at the Thomas Michael ...
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.
“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer.“We are proud to ...
The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...
17h
The Cool Down on MSNTeen scientist makes stunning breakthrough that could slash costs of lifesaving drugs: 'I cannot describe this feeling'
"This could be a huge step." Teen scientist makes stunning breakthrough that could slash costs of lifesaving drugs: 'I cannot ...
During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...
RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.
The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results